{
    "2021-08-29": [
        [
            {
                "time": "2021-08-29",
                "original_text": "智飞生物上半年盈利近55亿元 同比大增265%",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "盈利",
                        "同比大增",
                        "265%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-29",
                "original_text": "智飞生物(300122.SZ)上半年归母净利润同比增265%至54.91亿元",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "归母净利润",
                        "同比增",
                        "54.91亿元"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-29",
                "original_text": "智飞生物2021年中报净利同比增长265% 上半年研发投入近8亿",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "中报",
                        "净利增长",
                        "研发投入"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-29",
                "original_text": "智飞生物：上半年净利润54.91亿元 同比增265%",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "净利润",
                        "同比增",
                        "54.91亿元"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-29",
                "original_text": "医药行业周报：疫情常态化 疫苗产业链值得长期关注",
                "features": {
                    "keywords": [
                        "医药行业",
                        "疫情常态化",
                        "疫苗产业链",
                        "长期关注"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-29",
                "original_text": "智飞生物：上半年净利润同比增长264.94%",
                "features": {
                    "keywords": [
                        "智飞生物",
                        "净利润",
                        "同比增长",
                        "264.94%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-29",
                "original_text": "中泰证券维持智飞生物买入评级：重组新冠疫苗三期数据具备全球竞争力，看好下半年出口加速",
                "features": {
                    "keywords": [
                        "中泰证券",
                        "智飞生物",
                        "买入评级",
                        "重组新冠疫苗",
                        "全球竞争力",
                        "出口加速"
                    ],
                    "sentiment_score": 0.95,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-08-29",
                "original_text": "新冠疫苗重大利好：智飞生物“重组蛋白”路径产品Ⅲ期临床即将收官 Delta变异株防护率77.54%",
                "features": {
                    "keywords": [
                        "新冠疫苗",
                        "智飞生物",
                        "重组蛋白",
                        "Ⅲ期临床",
                        "Delta变异株",
                        "防护率77.54%"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}